ABROCITINIB for Psoriasis: Side Effects & Safety Data
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
There are 44 adverse event reports in the FDA FAERS database where ABROCITINIB was used for Psoriasis.
Most Reported Side Effects for ABROCITINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Drug ineffective | 398 | 12.6% | 0 | 5 |
| Condition aggravated | 316 | 10.0% | 0 | 18 |
| Off label use | 269 | 8.5% | 1 | 17 |
| Therapeutic product effect incomplete | 186 | 5.9% | 2 | 4 |
| Pruritus | 171 | 5.4% | 1 | 13 |
| Rash | 134 | 4.2% | 0 | 13 |
| Nausea | 130 | 4.1% | 0 | 6 |
| Dermatitis atopic | 110 | 3.5% | 0 | 6 |
| Headache | 85 | 2.7% | 1 | 4 |
| Acne | 73 | 2.3% | 0 | 1 |
| Fatigue | 70 | 2.2% | 0 | 5 |
| Dizziness | 63 | 2.0% | 1 | 7 |
| Eczema | 63 | 2.0% | 0 | 3 |
| Product dose omission issue | 52 | 1.6% | 0 | 0 |
| Therapeutic response unexpected | 52 | 1.6% | 0 | 1 |
Other Indications for ABROCITINIB
Dermatitis atopic (1,616)
Eczema (246)
Pruritus (61)
Dermatitis (41)
Product used for unknown indication (34)
Neurodermatitis (27)
Rash erythematous (23)
Rash (20)
Lichenification (17)
Dermatitis contact (12)
Other Drugs Used for Psoriasis
APREMILAST (76,127)
SECUKINUMAB (58,471)
ADALIMUMAB (56,634)
RISANKIZUMAB-RZAA (40,890)
ETANERCEPT (30,483)
USTEKINUMAB (21,763)
IXEKIZUMAB (16,569)
GUSELKUMAB (11,736)
CERTOLIZUMAB PEGOL (8,179)
METHOTREXATE (6,628)